Histone deacetylase inhibitors and cancer: from cell biology to the clinic
- 1 March 2005
- journal article
- review article
- Published by Elsevier in European Journal of Cell Biology
- Vol. 84 (2-3) , 109-121
- https://doi.org/10.1016/j.ejcb.2004.12.010
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Polyisoprenylated Benzophenone, Garcinol, a Natural Histone Acetyltransferase Inhibitor, Represses Chromatin Transcription and Alters Global Gene ExpressionJournal of Biological Chemistry, 2004
- Updated results from a phase I trial of the histone deacetylase (HDAC) inhibitor MS-275 in patients with refractory solid tumorsJournal of Clinical Oncology, 2004
- Enhanced Radiation-Induced Cell Killing and Prolongation of γH2AX Foci Expression by the Histone Deacetylase Inhibitor MS-275Cancer Research, 2004
- Small Molecule Modulators of Histone Acetyltransferase p300Journal of Biological Chemistry, 2003
- Histone deacetylases (HDACs): characterization of the classical HDAC familyBiochemical Journal, 2003
- Identifying Molecular Targets Mediating the Anticancer Activity of Histone Deacetylase Inhibitors: A Work in ProgressCurrent Cancer Drug Targets, 2002
- The promise of retinoids to fight against cancerNature Reviews Cancer, 2001
- HATs on and beyond chromatinCurrent Opinion in Cell Biology, 2001
- A tale of histone modificationsGenome Biology, 2001
- Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemiaNature, 1998